Suzhou Zelgen BiopharmaceuticalsLtd Balance Sheet Health
Financial Health criteria checks 4/6
Suzhou Zelgen BiopharmaceuticalsLtd has a total shareholder equity of CN¥1.6B and total debt of CN¥967.3M, which brings its debt-to-equity ratio to 60.4%. Its total assets and total liabilities are CN¥3.1B and CN¥1.5B respectively.
Key information
60.4%
Debt to equity ratio
CN¥967.30m
Debt
Interest coverage ratio | n/a |
Cash | CN¥2.41b |
Equity | CN¥1.60b |
Total liabilities | CN¥1.50b |
Total assets | CN¥3.10b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 688266's short term assets (CN¥2.7B) exceed its short term liabilities (CN¥1.2B).
Long Term Liabilities: 688266's short term assets (CN¥2.7B) exceed its long term liabilities (CN¥295.8M).
Debt to Equity History and Analysis
Debt Level: 688266 has more cash than its total debt.
Reducing Debt: 688266's debt to equity ratio has increased from 2.8% to 60.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 688266 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 688266 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.